Hepatic Disease

 
Bariatric Surgery Halves Adverse CVD Events in Patients with NAFLD, Severe Obesity
November 16, 2022

Bariatric surgery reduced by half the risk of CV events including myocardial infarction, heart failure, and stroke compared to nonsurgical care.

Cardiometabolic Disease Update: 12 Studies
October 12, 2022

Studies of cardiometabolic disease pathophysiology, prevention, and treatment make science news every day. Find 12 here, at-a-glance.

ADA, EASD Release Update on Management of Hyperglycemia in Type 2 Diabetes
September 23, 2022

The new consensus recommends holistic, person centered care focused on glycemic and weight management, CV risk reduction, and cardiorenal organ protection.

Less Than One-third of Adults with HCV Get Timely Treatment, According to New CDC Report
August 10, 2022

Timely initiation of DAA treatment, regardless of insurance type, is crucial in reducing HCV-related death, disparity, and transmission, concluded CDC researchers.

NAFLD Raises Risk of Incident Heart Failure with Increased Risk as Disease Worsens
August 04, 2022

A diagnosis of NAFLD was associated with a 50% greater risk of new-onset heart failure in a meta-analysis comprised of more than 11 million individuals.

Novel Liquid Biopsy for NASH is Highly Accurate, Sensitive, Specific, and Reliable
July 19, 2022

Clinical research into treatments for NASH is hampered by the need for invasive biopsies but a new blood test using 2 biomarkers could be a game changer, say study authors.

Management of Nonalcoholic Fatty Liver Disease in Adults: Guidelines for Primary Care Clinicians
July 15, 2022

An overview of recommendations from the American Association of Clinical Endocrinology for the management of NAFLD in adults.

Diagnosis of Nonalcoholic Fatty Liver Disease in Adults: Guidelines for Primary Care
July 14, 2022

Get an overview of the recent AACE guidelines for diagnosing NAFLD in adults in primary care settings.

Obeticholic Acid in NASH Significantly Improves Liver Fibrosis: Topline Phase 3 Study Findings 
July 12, 2022

Results of the prespecified analysis from the REGENERATE trial confirm 2019 data demonstrating statistically significant improvement in fibrosis without worsening NASH.

Licogliflozin, a SGLT-1/2 Inhibitor, Shows Potential for Treatment of NASH
June 22, 2022

The sodium-glucose cotransporter 1/2 inhibitor at 150 mg was associated with a significant 32% reduction in liver enzyme levels in a phase 2a clinical trial.